Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease

BACKGROUND AND AIM: Anti‐tumor necrosis factor‐α (anti‐TNF‐α) agents have been used for inflammatory bowel disease; however, it has up to 30% nonresponse rate. Identifying molecular pathways and finding reliable diagnostic biomarkers for patient response to anti‐TNF‐α treatment are needed. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Tung On, Vadakekolathu, Jayakumar, Foulds, Gemma Ann, Du, Guodong, Dickins, Benjamin, Polytarchou, Christos, Rutella, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles ‐ Gastroenterology (Experimental)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303672/
https://www.ncbi.nlm.nih.gov/pubmed/34931384
http://dx.doi.org/10.1111/jgh.15764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303672/
https://www.ncbi.nlm.nih.gov/pubmed/34931384
http://dx.doi.org/10.1111/jgh.15764

Ejemplares similares